Evidence map›Paper›PMID 34226437›Full record

ArticleAnnals of transplantation2021

Liver Transplantation: A 10-Year Low-Volume Transplant Center Experience in Kazakhstan.

Jamilya Saparbay, Janat Spatayev, Abylaikhan Sharmenov, Shokan Aytbayev, Aizhan Uristenova, Adilbek Mukazhanov, Asan Zhexembayev

Open access · greenAbstract read
In one paragraph

Article in Annals of transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jamilya SaparbayDepartment of Hepatology, Gastroenterology, and Organ Transplantation, LLP National Research Oncology Center, Nur-Sultan, Kazakhstan.
Janat SpatayevDepartment of Hepatology, Gastroenterology, and Organ Transplantation, LLP National Research Oncology Center, Nur-Sultan, Kazakhstan.
Abylaikhan SharmenovDepartment of Hepatology, Gastroenterology, and Organ Transplantation, LLP National Research Oncology Center, Nur-Sultan, Kazakhstan.
Shokan AytbayevDepartment of Hepatology, Gastroenterology, and Organ Transplantation, LLP National Research Oncology Center, Nur-Sultan, Kazakhstan.
Aizhan UristenovaDepartment of Hepatology, Gastroenterology, and Organ Transplantation, LLP National Research Oncology Center, Nur-Sultan, Kazakhstan.
Adilbek MukazhanovDepartment of Hepatology, Gastroenterology, and Organ Transplantation, LLP National Research Oncology Center, Nur-Sultan, Kazakhstan.
Asan ZhexembayevDepartment of Hepatology, Gastroenterology, and Organ Transplantation, LLP National Research Oncology Center, Nur-Sultan, Kazakhstan.
KazMunayGas (Kazakhstan) · KZNational Research Center for Maternal and Child Health · KZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Liver transplantation is considered to be the best available treatment option for patients with liver failure. In Kazakhstan, the liver transplantation program was established a decade ago. In this study, we analyzed a low-volume transplant center experience of liver transplantation in Kazakhstan. MATERIAL AND METHODS Clinical data of the 64 consecutive liver transplantations from deceased and living donors between 2010 and 2020 were retrieved from electronic records. All data were retrospectively analyzed. RESULTS A total of 64 liver transplantations, 11 from deceased donors and 53 from living donors, were carried out in our center between 2010 and 2020. The mean age of the recipient was 44 years, 53% were female, and 47% were male. Hepatitis B+hepatitis D infection was the most common cause of end-stage liver disease (21 cases; 32.8%). The overall patient survival rates for 1, 3, and 5 years were 75%, 69.5%, and 59.6%, respectively, for recipients of a liver transplant from a living donor and 54.5%, 45.5%, and 39% for recipients of a liver transplant from a deceased donor. CONCLUSIONS Our clinical outcomes had a high rate of biliary and vascular complications that led to a low survival rate of the recipients. Starting the transplant program in Kazakhstan faced various challenges. In the early period, most transplantations were performed in collaboration with or under the guidance of transplant teams from Russia, Turkey, and South Korea. Improving surgical techniques and protocols of pre- and posttransplantation management could reduce the complications after transplantation.

Indexed as

End Stage Liver DiseaseLiver TransplantationAdolescentAdultCarcinoma, HepatocellularFemaleHepatitis BHepatitis DHumansKazakhstanLiver NeoplasmsLiving DonorsMaleMiddle AgedRetrospective StudiesTreatment Outcome

Identifiers

PMID34226437
PMCPMC8272395
OpenAlexW3173857889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.